• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素受体调控膀胱癌中 CD44 的表达。

Androgen Receptor Regulates CD44 Expression in Bladder Cancer.

机构信息

Department of Pathology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado.

Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado - Anschutz Medical Campus, Aurora, Colorado.

出版信息

Cancer Res. 2021 Jun 1;81(11):2833-2846. doi: 10.1158/0008-5472.CAN-20-3095. Epub 2021 Mar 9.

DOI:10.1158/0008-5472.CAN-20-3095
PMID:33687952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8782536/
Abstract

The androgen receptor (AR) is important in the development of both experimental and human bladder cancer. However, the role of AR in bladder cancer growth and progression is less clear, with literature indicating that more advanced stage and grade disease are associated with reduced AR expression. To determine the mechanisms underlying these relationships, we profiled AR-expressing human bladder cancer cells by AR chromatin immunoprecipitation sequencing and complementary transcriptomic approaches in response to stimulation by the synthetic androgen R1881. functional genomics consisting of pooled shRNA or pooled open reading frame libraries was employed to evaluate 97 genes that recapitulate the direction of expression associated with androgen stimulation. Interestingly, we identified CD44, the receptor for hyaluronic acid, a potent biomarker and driver of progressive disease in multiple tumor types, as significantly associated with androgen stimulation. CRISPR-based mutagenesis of androgen response elements associated with CD44 identified a novel silencer element leading to the direct transcriptional repression of CD44 expression. In human patients with bladder cancer, tumor AR and CD44 mRNA and protein expression were inversely correlated, suggesting a clinically relevant AR-CD44 axis. Collectively, our work describes a novel mechanism partly explaining the inverse relationship between AR and bladder cancer tumor progression and suggests that AR and CD44 expression may be useful for prognostication and therapeutic selection in primary bladder cancer. SIGNIFICANCE: This study describes novel AREs that suppress CD44 and an expected inverse correlation of AR-CD44 expression observed in human bladder tumors.

摘要

雄激素受体 (AR) 在实验性和人类膀胱癌的发展中都很重要。然而,AR 在膀胱癌生长和进展中的作用尚不清楚,文献表明,更晚期和更高级别的疾病与 AR 表达减少有关。为了确定这些关系的机制,我们通过 AR 染色质免疫沉淀测序和互补转录组学方法对表达 AR 的人膀胱癌细胞进行了分析,以响应合成雄激素 R1881 的刺激。采用功能基因组学方法,包括 pooled shRNA 或 pooled open reading frame libraries,评估了 97 个基因,这些基因的表达方向与雄激素刺激相关。有趣的是,我们发现了 CD44,它是透明质酸的受体,是多种肿瘤类型中具有强大生物标志物和进展性疾病驱动作用的因子,与雄激素刺激显著相关。与 CD44 相关的雄激素反应元件的 CRISPR 诱变确定了一个新的沉默元件,导致 CD44 表达的直接转录抑制。在患有膀胱癌的人类患者中,肿瘤 AR 和 CD44 mRNA 和蛋白表达呈负相关,提示存在临床相关的 AR-CD44 轴。总的来说,我们的工作描述了一种新的机制,部分解释了 AR 与膀胱癌肿瘤进展之间的反比关系,并表明 AR 和 CD44 表达可能对原发性膀胱癌的预后和治疗选择有用。意义:本研究描述了抑制 CD44 的新型 ARE 以及在人类膀胱癌中观察到的预期的 AR-CD44 表达的反比关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/7c8b72e57836/nihms-1683014-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/4f708289c7f9/nihms-1683014-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/2adb2580ed31/nihms-1683014-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/85e02eceba56/nihms-1683014-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/2b4e71421505/nihms-1683014-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/8c133d9e49e5/nihms-1683014-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/9d1111f9a572/nihms-1683014-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/7c8b72e57836/nihms-1683014-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/4f708289c7f9/nihms-1683014-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/2adb2580ed31/nihms-1683014-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/85e02eceba56/nihms-1683014-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/2b4e71421505/nihms-1683014-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/8c133d9e49e5/nihms-1683014-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/9d1111f9a572/nihms-1683014-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/147d/8782536/7c8b72e57836/nihms-1683014-f0007.jpg

相似文献

1
Androgen Receptor Regulates CD44 Expression in Bladder Cancer.雄激素受体调控膀胱癌中 CD44 的表达。
Cancer Res. 2021 Jun 1;81(11):2833-2846. doi: 10.1158/0008-5472.CAN-20-3095. Epub 2021 Mar 9.
2
ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.ELK1在膀胱癌细胞中被雄激素上调,并促进肿瘤进展。
Oncotarget. 2015 Oct 6;6(30):29860-76. doi: 10.18632/oncotarget.5007.
3
Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.CD44 在肌层浸润性膀胱癌中的预测价值及其与 IL-6 信号的关系。
Ann Surg Oncol. 2018 Nov;25(12):3518-3526. doi: 10.1245/s10434-018-6706-0. Epub 2018 Aug 20.
4
Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.携带 E1A-雄激素受体的膀胱癌特异性腺病毒在膀胱癌中的抗肿瘤作用。
Gene Ther. 2012 Nov;19(11):1065-74. doi: 10.1038/gt.2011.180. Epub 2012 Jan 5.
5
Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition.雄激素受体通过促进上皮-间质转化诱导膀胱癌进展。
Andrologia. 2014 Dec;46(10):1128-33. doi: 10.1111/and.12203. Epub 2013 Dec 16.
6
Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer.雄激素受体信号调节膀胱癌中的细胞生长和对多柔比星的敏感性。
J Urol. 2012 Jul;188(1):276-86. doi: 10.1016/j.juro.2012.02.2554. Epub 2012 May 16.
7
Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.二氢睾酮上调雄激素受体阳性膀胱癌细胞中表皮生长因子受体和 ERBB2 的表达。
Endocr Relat Cancer. 2011 Jul 4;18(4):451-64. doi: 10.1530/ERC-11-0010. Print 2011 Aug.
8
CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach.CD44 剪接变异体(CD44v3)通过 Akt/ERK/STAT3 通路促进膀胱尿路上皮癌的进展:新的治疗方法。
J Cancer Res Clin Oncol. 2019 Nov;145(11):2649-2661. doi: 10.1007/s00432-019-03024-9. Epub 2019 Sep 16.
9
Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.孤儿核受体 TLX 通过抑制雄激素受体转录促进去势抵抗性前列腺癌的雄激素不敏感。
Oncogene. 2018 Jun;37(25):3340-3355. doi: 10.1038/s41388-018-0198-z. Epub 2018 Mar 20.
10
Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2.长非编码 RNA SOX2OT 通过调节 SOX2 促进膀胱癌干细胞的干性表型。
Mol Cancer. 2020 Feb 4;19(1):25. doi: 10.1186/s12943-020-1143-7.

引用本文的文献

1
Recent advances in understanding the role of sex hormone receptors in urothelial cancer.了解性激素受体在尿路上皮癌中作用的最新进展。
Oncol Res. 2025 May 29;33(6):1255-1270. doi: 10.32604/or.2025.062142. eCollection 2025.
2
Sex differences in bladder cancer: understanding biological and clinical implications.膀胱癌中的性别差异:理解生物学和临床意义。
Biol Sex Differ. 2025 May 13;16(1):31. doi: 10.1186/s13293-025-00715-6.
3
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.非前列腺恶性肿瘤中的雄激素受体信号传导:挑战与机遇

本文引用的文献

1
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.肌肉浸润性膀胱癌的分子亚型分布受性别特异性差异驱动。
Eur Urol Oncol. 2020 Aug;3(4):420-423. doi: 10.1016/j.euo.2020.02.010. Epub 2020 Mar 20.
2
Cellular rewiring in lethal prostate cancer: the architect of drug resistance.致命性前列腺癌中的细胞重排:耐药性的建筑师。
Nat Rev Urol. 2020 May;17(5):292-307. doi: 10.1038/s41585-020-0298-8. Epub 2020 Mar 16.
3
Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?
Nat Rev Cancer. 2025 Feb;25(2):93-108. doi: 10.1038/s41568-024-00772-w. Epub 2024 Nov 25.
4
Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021.1990 年至 2021 年全球良性前列腺增生症、尿路感染、尿路结石、膀胱癌、肾癌和前列腺癌的负担。
Mil Med Res. 2024 Sep 18;11(1):64. doi: 10.1186/s40779-024-00569-w.
5
CD44 in Bladder Cancer.膀胱癌中的CD44
Cancers (Basel). 2024 Mar 18;16(6):1195. doi: 10.3390/cancers16061195.
6
Roles of Androgen Receptor Signaling in Urothelial Carcinoma.雄激素受体信号通路在尿路上皮癌中的作用
Cancers (Basel). 2024 Feb 10;16(4):746. doi: 10.3390/cancers16040746.
7
Small Cajal Body-Specific RNA12 Promotes Carcinogenesis through Modulating Extracellular Matrix Signaling in Bladder Cancer.小 Cajal 体特异性 RNA12 通过调节膀胱癌中的细胞外基质信号促进肿瘤发生。
Cancers (Basel). 2024 Jan 23;16(3):483. doi: 10.3390/cancers16030483.
8
Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes.膀胱癌中的性别二态性:病因、生物学、诊断及预后综述
Front Pharmacol. 2024 Jan 12;14:1326627. doi: 10.3389/fphar.2023.1326627. eCollection 2023.
9
Cytoplasmic Androgen Receptor, CD24 Expression and Smoking Intensity to Urothelial Carcinoma of the Bladder Invasiveness: A Cross-Sectional Study.细胞质雄激素受体、CD24表达及吸烟强度与膀胱尿路上皮癌侵袭性的关系:一项横断面研究
Res Rep Urol. 2023 Nov 1;15:485-494. doi: 10.2147/RRU.S433705. eCollection 2023.
10
Targeting androgen receptor (AR) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR-expressing prostate cancer cell lines.用一种合成肽靶向雄激素受体(AR)可增加三阴性乳腺癌和表达AR的前列腺癌细胞系中的细胞凋亡。
Cancer Rep (Hoboken). 2024 Jan;7(1):e1922. doi: 10.1002/cnr2.1922. Epub 2023 Oct 30.
2020 年非转移性去势抵抗性前列腺癌的治疗:哪种方法最佳?
Urol Oncol. 2020 Apr;38(4):129-136. doi: 10.1016/j.urolonc.2019.11.007. Epub 2020 Jan 15.
4
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.雄激素受体表达在非肌肉浸润性膀胱癌中的作用:系统评价和荟萃分析。
Histol Histopathol. 2020 May;35(5):423-432. doi: 10.14670/HH-18-189. Epub 2019 Dec 5.
6
Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy.膀胱癌对顺铂为基础的新辅助化疗反应的表型特征的预测价值。
Urol Oncol. 2019 Sep;37(9):572.e1-572.e11. doi: 10.1016/j.urolonc.2019.06.020. Epub 2019 Jul 17.
7
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.超生理雄激素通过雄激素受体介导的 DNA 损伤抑制前列腺癌生长。
J Clin Invest. 2019 Jul 16;129(10):4245-4260. doi: 10.1172/JCI127613.
8
The interaction of gender and smoking on bladder cancer risks.性别和吸烟对膀胱癌风险的交互作用。
Curr Opin Urol. 2019 May;29(3):249-255. doi: 10.1097/MOU.0000000000000602.
9
Identification of human silencers by correlating cross-tissue epigenetic profiles and gene expression.通过关联跨组织表观遗传谱和基因表达鉴定人类沉默子。
Genome Res. 2019 Apr;29(4):657-667. doi: 10.1101/gr.247007.118. Epub 2019 Mar 18.
10
Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.橄榄苦苷抑制 STAT3/AR 信号轴并抑制恩杂鲁胺耐药性前列腺癌。
Sci Rep. 2018 Nov 23;8(1):17307. doi: 10.1038/s41598-018-35612-z.